New preprint: genetic variation and healthcare spending Across ~1.43M people, we identify hundreds of cost-associated variants, strong HLA signals, and higher costs among carriers of rare pathogenic variants in genes including BRCA1/2 and APC. www.medrxiv.org/content/10.6...

Quantifying the contribution of genetic variation to healthcare expenditure across diverse healthcare systems

Healthcare systems must balance rising costs with the delivery of effective care, yet the factors underlying large inter-individual differences in healthcare expenditure remain incompletely understood...

medrxiv.org

(3/4) @padraigdixon.bsky.social (University of Oxford) will present a novel approach to estimate long-term cost-effectiveness of health interventions without RCTs/Markov models.‬ Using a prostate cancer prevention case study, he’ll show how MR can link genetic liability to healthcare costs & QALYs.

Modelling the potential contributions of polygenic risk stratification to cost-effective screening for prostate cancer https://www.medrxiv.org/content/10.1101/2025.05.19.25327897v1

#january Day 5 As #genomic testing evolves, what does this mean for risk-rated #insurance? This article led by former CPM JRF @padraigdixon.bsky.social discusses emerging challenges:

Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges | Health Economics, Policy and Law | Cambridge Core

Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges

buff.ly

The changing landscape of genetics and insurance in the UK - report on an event hosted by the Centre for Personalised Medicine, Oxford and the British Society for Genetic Medicine. bsgm.org.uk/media/12689/...